Camilla Sylvest, regional vice president of the world's largest Danish insulin manufacturer Novo Nordisk, is scheduled to arrive in Dhaka today for a short visit.
Sylvest is responsible for Novo Nordisk operations in 21 countries, including Bangladesh, Asean countries, Australia and New Zealand. Before coming to South East Asia, Sylvest was the vice president for Novo Nordisk, Germany.
During her stay, she will attend the launch of Tresiba: a once daily ultra-long acting basal insulin, Novo Nordisk said in a statement yesterday.
She will also visit the factory of Eskayef Bangladesh Ltd, which has a dedicated formulation and packaging facility of insulin, exclusively for Novo Nordisk.
Sylvest will also meet the senior officials of Transcom Distribution Company Ltd, which is the authorised distributor of Novo Nordisk insulin in Bangladesh.
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy.
The company employs around 38,000 people in 75 countries and markets its products in more than 180 countries.
In Bangladesh, Novo Nordisk has been working for changing diabetes for over 50 years in close collaboration with the Diabetic Association of Bangladesh.